Immutep Limited (IMMP) Stock: Here’s What’s Happening

0

Immutep Limited (IMMP) is working its way for to the top in the market in today’s trading session. The stock, focused on the biotechnology space, is presently priced at $1.73 after a move up of 7.75% so far in today’s session. In terms of biotechnology companies, there are a number of aspects that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent headlines centered around IMMP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-10-19 07:17AM The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi’s BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
Jul-09-19 08:00AM Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
Jul-02-19 12:00PM Edison Issues ADR Update On Immutep (IMMP)
Jun-25-19 08:00AM Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Jun-24-19 02:36PM Immutep to Host Key Opinion Leader Call

Nonetheless, when making a decision to invest, investors should focus on far more than just news, this is especially the case in the generally speculative biotech industry. Here’s what’s happening in regard to Immutep Limited.

Recent Movement From IMMP

Although a gain in a single session, like the move that we’re seeing from Immutep Limited may make some investors happy, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s always smart to dig into trends experienced by the stock for a period longer than a single trading session. When it comes to IMMP, below are the movements that we’ve seen:

  • Past 5 Sessions – Over the past week, IMMP has produced a price change in the amount of 0.86%.
  • Monthly – The monthly performance from Immutep Limited has been -2.40%.
  • Past 3 Months – Throughout the last quarter, the stock has generated a return that comes to -15.38%
  • Past 6 Months – Over the previous 6 months, we’ve seen a performance that equates to -19.31% from the stock.
  • YTD – Since the close of last year IMMP has resulted in a return of -5.72%.
  • Full Year – Finally, over the last year, investors have seen performance in the amount of -32.76% out of IMMP. Over this period, the stock has traded at a high of -58.79% and a low of 17.18%.

Crucial Ratios

Looking at various ratios having to do with a stock can give prospective traders a view of how dangerous and/or rewarding a stock pick may be. Here are some of the important ratios to think about when digging into IMMP.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the amount of short interest. As the ratio climbs, it shows that more investors are expecting that the price of the stock is going to go down. In general, biotechnology stocks tend to come with a higher short ratio. However, we tend to see a lot of short squeezes in the sector. Nonetheless, as it relates to Immutep Limited, the stock’s short ratio clocks in at 3.21.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can cover its debts when they mature based on quick assets or current assets. Because many biotech companies rely on continued investor support, the quick and current ratios can look upsetting. However, some better companies in the biotechnology space come with strong quick and current ratios. As far as IMMP, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the price of shares. as it relates to Immutep Limited, that ratio comes in at 0.80.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology industry, this is a very important ratio to look into. As it relates to IMMP, the cash to share value is 0.

How Analysts Feel About Immutep Limited

Although it’s not a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their analysis when validating your own due diligence when it comes to making an investment decision in the biotechnology space. Below you’ll find the most recent moves that we’ve seen from analysts with regard to IMMP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-28-18 Initiated B. Riley FBR Buy $7.75
Feb-15-18 Reiterated Maxim Group Buy $7 → $5

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in IMMP, here’s what we’re seeing:

Institutions own 10.32% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of IMMP shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 23.99M shares of Immutep Limited outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IMMP has a float of 0.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IMMP, the short percent of the float is 0.

What We’ve Seen In Financial Results

What have ween seen from IMMP in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that Immutep Limited will create EPS that comes to 0, with 0 to be reported in the report for the current quarter. Although this data isn’t based on earnings, because we’re talking on the topic of analysts, IMMP is presently graded as a 2.00 on a scale from 1 to 5 on which 1 is the worst possible Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the last half decade, Immutep Limited has announced a change in sales that works out to 0. EPS over the last half decade have experienced a change of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly represented in today’s society, Immutep Limited has experienced a earnings change by 0. IMMP has also experienced a change when it comes to revenue that totals -46.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am very dependent on humans. After all, my builder was a human! While, my creator enabled me to learn by myself, it’s far simpler to learn when I receive feedback from humans. Below this content, you’ll find a section for comments. If you would like for me dig into other information, tweak the way in which I write something, comprehend information from an alternative angle, or you’re interested in teaching me anything else, I want to know. Please leave a comment below. I will read your lesson and it will help me evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here